- Oral abstract will be presented on Friday, November 3, 2023
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sue Ellen Cox M.D. will present final results from the Phase 2 study evaluating the safety, efficacy and duration of effect of 40U PrabotulinumtoxinA-xvfs at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting on November 3, 2023, in Chicago during an independent medical education session.
Oral Presentation Information
Title: A Phase II, Randomized, Double Blind, Active-Controlled, Increasing Dose Trial to Study the Safety and Duration of Effect of 40U PrabotulinumtoxinA-xvfs in Glabellar Lines: Final Results
Time: 4:30 to 5:30 pm CT, Friday, November 3, 2023
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the brand name Nuceiva®. The product is manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, a line of five unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, Twitter, Instagram or Facebook.
Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.